<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> has shown a significant increase in incidence in recent years </plain></SENT>
<SENT sid="1" pm="."><plain>It is thought that the development of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>), followed by <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">columnar-lined esophagus</z:e> and the development of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, leads to invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The exact pathogenesis of this process, the diagnosis and differentiation of the metaplastic and dysplastic esophageal lesions have yet to be determined </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this immunohistochemical study was to investigate the expression of pro-tumorigenic enzyme platelet 12-lipoxygenase (p12LOX) using two new available antibodies in non-dysplastic and dysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The stem cell markers nestin, CD117 and CD44, were then evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>The comparative group included <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> <z:mp ids='MP_0001853'>carditis</z:mp>, gastric <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> and colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>The overexpression of p12LOX detected by two specific antibodies in the non-dysplastic and dysplastic Barrett's mucosa clearly demonstrated that this enzyme plays an important role in the development of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>